All In Biotech

Drug Trial Radar · NCT05995704

Evaluation of Apraglutide on Gastric Emptying

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Center, Multiple-Dose, Parallel Trial Evaluating the Impact of Apraglutide on Gastric Emptying of Liquids in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Mar 2, 2023

Primary completion

Jul 24, 2023

Study completion Jul 24, 2023

Sponsor

Lead sponsor
VectivBio AGIndustry
Sponsor type
Industry
First posted
Aug 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to assess the effect of apraglutide on gastric emptying of liquids in healthy subjects, as measured by the PK of acetaminophen mixed with a liquid meal.

Conditions

  • Healthy Subjects

Interventions

  • ApraglutideDrug

    Peptide analogue of GLP-2

  • PlaceboDrug

    Matching placebo to apraglutide

  • AcetaminophenDrug

    Acetaminophen mixed with a liquid meal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration (Cmax) of acetaminophenTime frame: 0-300 Minutes
  2. Time at which the maximum plasma concentration is observed (tmax) of acetaminophenTime frame: 0-300 Minutes
  3. Area under the acetaminophen concentration-time curve: AUCinf (AUClast in case AUCinf cannot be estimated)Time frame: 0-14 hours
  4. Area under the acetaminophen concentration-time curve: AUC0-300minTime frame: 0-300 Minutes
  5. Area under the acetaminophen concentration-time curve: AUC0-60minTime frame: 0-60 Minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Clinical Research Unit

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.